chr20-23049378-C-T

Variant summary

Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_000361.3(THBD):​c.127G>A​(p.Ala43Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00368 in 1,598,276 control chromosomes in the GnomAD database, including 13 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. A43A) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0025 ( 1 hom., cov: 33)
Exomes 𝑓: 0.0038 ( 12 hom. )

Consequence

THBD
NM_000361.3 missense

Scores

1
17

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:6O:2

Conservation

PhyloP100: -1.09
Variant links:
Genes affected
THBD (HGNC:11784): (thrombomodulin) The protein encoded by this intronless gene is an endothelial-specific type I membrane receptor that binds thrombin. This binding results in the activation of protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin generated. Mutations in this gene are a cause of thromboembolic disease, also known as inherited thrombophilia. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0040130317).
BP6
Variant 20-23049378-C-T is Benign according to our data. Variant chr20-23049378-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 12718.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=2, Benign=3}. Variant chr20-23049378-C-T is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.00252 (383/151910) while in subpopulation AMR AF= 0.00446 (68/15254). AF 95% confidence interval is 0.00361. There are 1 homozygotes in gnomad4. There are 169 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High AC in GnomAd4 at 383 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
THBDNM_000361.3 linkuse as main transcriptc.127G>A p.Ala43Thr missense_variant 1/1 ENST00000377103.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
THBDENST00000377103.3 linkuse as main transcriptc.127G>A p.Ala43Thr missense_variant 1/1 NM_000361.3 P1

Frequencies

GnomAD3 genomes
AF:
0.00252
AC:
383
AN:
151782
Hom.:
1
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000822
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00446
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000424
Gnomad FIN
AF:
0.0000941
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00400
Gnomad OTH
AF:
0.00288
GnomAD3 exomes
AF:
0.00200
AC:
432
AN:
215894
Hom.:
0
AF XY:
0.00199
AC XY:
237
AN XY:
118936
show subpopulations
Gnomad AFR exome
AF:
0.00108
Gnomad AMR exome
AF:
0.00139
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000829
Gnomad FIN exome
AF:
0.000328
Gnomad NFE exome
AF:
0.00357
Gnomad OTH exome
AF:
0.00166
GnomAD4 exome
AF:
0.00381
AC:
5506
AN:
1446366
Hom.:
12
Cov.:
34
AF XY:
0.00377
AC XY:
2709
AN XY:
718436
show subpopulations
Gnomad4 AFR exome
AF:
0.000693
Gnomad4 AMR exome
AF:
0.00177
Gnomad4 ASJ exome
AF:
0.0000390
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00112
Gnomad4 FIN exome
AF:
0.000534
Gnomad4 NFE exome
AF:
0.00459
Gnomad4 OTH exome
AF:
0.00342
GnomAD4 genome
AF:
0.00252
AC:
383
AN:
151910
Hom.:
1
Cov.:
33
AF XY:
0.00228
AC XY:
169
AN XY:
74278
show subpopulations
Gnomad4 AFR
AF:
0.000820
Gnomad4 AMR
AF:
0.00446
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000423
Gnomad4 FIN
AF:
0.0000941
Gnomad4 NFE
AF:
0.00400
Gnomad4 OTH
AF:
0.00285
Alfa
AF:
0.00346
Hom.:
3
Bravo
AF:
0.00278
TwinsUK
AF:
0.00135
AC:
5
ALSPAC
AF:
0.00389
AC:
15
ESP6500AA
AF:
0.00186
AC:
8
ESP6500EA
AF:
0.00453
AC:
38
ExAC
AF:
0.00176
AC:
210
Asia WGS
AF:
0.000578
AC:
2
AN:
3476

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:6Other:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2
Likely benign, criteria provided, single submitterclinical testingGeneDxNov 19, 2019In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 19625716, 28752844, 23332921, 24853860, 9198186, 25079699, 20595690) -
Uncertain significance, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicJun 14, 2022BP4 -
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 29, 2024- -
Atypical hemolytic-uremic syndrome with thrombomodulin anomaly Uncertain:1Benign:1Other:1
Benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaMar 06, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
risk factor, no assertion criteria providedliterature onlyOMIMJul 23, 2009- -
Uncertain significance, criteria provided, single submitterclinical testingClinical Genomics Laboratory, Washington University in St. LouisFeb 25, 2024The THBD c.127G>A (p.Ala43Thr) variant has been observed in multiple individuals with atypical hemolytic uremic syndrome (aHUS) (Gaut JP et al., PMID: 28752844; Vaught AJ et al., PMID: 29563339; Fremeaux-Bacchi V et al., PMID: 23307876). However, this variant has also been observed in some apparently unaffected relatives, suggesting incomplete penetrance or variable expressivity of the phenotype (Delvaeye M et al., PMID: 19625716). This variant is observed on 502/247,256 alleles in the general population (gnomAD v2.1.1). Computational predictors suggest that the variant does not impact THBD function, however, functional studies show that this alanine to threonine amino acid change results in decreased capacity to inactivate C3b (Delvaeye M et al., PMID: 19625716). Due to conflicting information and based on the ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), the clinical significance of the THBD c.127G>A (p.Ala43Thr) variant is uncertain at this time. -
Atypical hemolytic-uremic syndrome Benign:1Other:1
Likely benign, criteria provided, single submitterclinical testingGenome Diagnostics Laboratory, The Hospital for Sick ChildrenJul 07, 2020- -
risk factor, no assertion criteria providedclinical testingSydney Genome Diagnostics, Children's Hospital WestmeadMar 06, 2018This patient is heterozygous for a variant, c.127G>A (p.Ala43Thr), in the THBD gene. This variant (dbSNP: rs1800576) has been previously reported in the Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/) with a minor allele frequency of 0.34% (172 out of 50152 alleles). This variant has also been previously reported in the heterozygote state in a man with recurrent atypical haemolytic uremic syndrome (aHUS) since infancy, with chronic renal failure and decreased serum C3 (Delvaeye et al 2009 N Engl J Med 361:345-357). The patient had affected and unaffected family members who were also heterozygote for this variant. In vitro functional studies by the same group showed the mutant p.Ala43Thr did not protect cultured cells against complement activation suggesting that this variant affects function. -
not specified Benign:1
Benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoAug 30, 2021- -
THBD-related disorder Benign:1
Likely benign, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesMar 12, 2020This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.084
BayesDel_addAF
Benign
-0.58
T
BayesDel_noAF
Benign
-0.61
CADD
Benign
5.0
DANN
Benign
0.97
DEOGEN2
Benign
0.15
T
Eigen
Benign
-1.2
Eigen_PC
Benign
-1.1
FATHMM_MKL
Benign
0.077
N
LIST_S2
Benign
0.36
T
MetaRNN
Benign
0.0040
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.7
L
MutationTaster
Benign
1.0
N
PrimateAI
Uncertain
0.55
T
PROVEAN
Benign
-0.39
N
REVEL
Benign
0.014
Sift
Benign
0.53
T
Sift4G
Benign
0.57
T
Polyphen
0.022
B
Vest4
0.051
MVP
0.15
ClinPred
0.0014
T
GERP RS
1.6
Varity_R
0.076
gMVP
0.42

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1800576; hg19: chr20-23030015; COSMIC: COSV101001938; API